Boceprevir-PegIFN-RBV tritherapy in treatment-experienced HCV genotype 1-HIV co-infected patients: response rate at W48 (ANRS-HC27 BocepreVIH Study)

Affiliation auteurs!!!! Error affiliation !!!!
TitreBoceprevir-PegIFN-RBV tritherapy in treatment-experienced HCV genotype 1-HIV co-infected patients: response rate at W48 (ANRS-HC27 BocepreVIH Study)
Type de publicationJournal Article
Year of Publication2014
AuteursFougerou-Leurent C., Poizot-Martin I., Teicher E., Rosenthal E., Alric L., Piroth L., Bourliere M., Guyader D., Molina J.M, Bellissant E.
JournalFUNDAMENTAL & CLINICAL PHARMACOLOGY
Volume28
Pagination64
Date PublishedMAY
Type of ArticleMeeting Abstract
ISSN0767-3981
Mots-clésBoceprevir, Hepatitis C, HIV co-infection, protease inhibitor